PROFARMA has transferred the technology for biosimilar somatropin to GMP facility

PROFARMA of Lithuania, VELIT Biopharmaceuticals GmbH of Austria and GENOVIOR BIOTECH of Taiwan have agreed on collaboration regarding biosimilar somatropin project.

PROFARMA has developed an efficient upstream and downstream processes as well as analytical methods for manufacturing of biosimilar somatropin at R&D scale and has transfered the technology to GMP facility in Taiwan.

PROFARMA has different biosimilar and biobetter technologies in it's pipeline. Company has developed and patented ProMER technology for the extension of the plasma half-life of biopharmaceuticals, involving recombinant fusion expression rather than chemical linkage, such as PEGylation.

 

Contacts
JSC "PROFARMA"


V.A. Graiciuno 6, LT-02241,
Vilnius, Lithuania


Tel. +370 5 2629761,
E-mail: info@profarma.lt